Monitoring of Clopidogrel-Related Platelet Inhibition: Correlation of Nonresponse with Clinical Outcome in Supra-Aortic Stenting
Why the study?
Does clopidogrel nonresponse increase the risk of adverse events in patients undergoing supra-aortic stenting?
Structured PICO
Does clopidogrel nonresponse increase the risk of adverse events in patients undergoing supra-aortic stenting?
P
Population
50 consecutive patients with symptomatic arteriosclerotic lesions scheduled for neuro-interventional stent placement of supra-aortic arteries supplying the brain, and 50 healthy blood donors serving as a control group for reference values.
I
Intervention
Clopidogrel nonresponse (assessed by point-of-care impedance aggregometry)
C
Comparator
Clopidogrel response
O
Outcome
Adverse events (including thromboembolic events and permanent neurologic deficit) after stent placementhard clinical
Clopidogrel nonresponse is significantly associated with an increased risk of thromboembolic adverse events in patients undergoing supra-aortic stenting.
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Clopidogrel nonresponse was associated with adverse events after supra-aortic stenting; hypothesis-generating and requires prospective confirmation before guiding therapy.
Cite This Study
Müller-Schunk et al. (2008) studied this question.